SEC-sourced researchBeta
PCRX
Pacira BioSciences, Inc.
Company comparison ↗
Data passport
- CIK
- 0001396814
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Feb 26, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 674,978,000.0000 | Feb 26, 2026 |
| December 2024 | 700,966,000.0000 | Feb 26, 2026 |
| December 2025 | 726,411,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 726,411,000.0000 | 7,034,000.0000 | 151,994,000.0000 | 1,264,917,000.0000 | 571,806,000.0000 | Feb 26, 2026 |
| December 2024 | 700,966,000.0000 | -99,560,000.0000 | 189,389,000.0000 | 1,553,516,000.0000 | 775,168,000.0000 | Feb 26, 2026 |
| December 2023 | 674,978,000.0000 | 41,955,000.0000 | 154,649,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $726.41M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $700.97M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | $7.03M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $151.99M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $1.26B | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $571.81M | December 2025 | Feb 26, 2026 | 10-K |